Amber Marie D'SOuza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amber Marie D'SOuza has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Alex Bondoc
Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2 shared publications- Alexander J. Towbin
Department of Radiology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
2 shared publications Anita Gupta
Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2 shared publicationsGreg Tiao
Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2 shared publicationsJaimie D. Nathan
Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2 shared publications- James I. Geller
Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA
2 shared publications
Latest Publications
- 28 September 2026
- Published by Wiley in Pediatric Blood & Cancer
Individualized Patient Education Using Virtual Reality to Prepare Families for Solid Tumor Surgery in Pediatric Oncology
Background/Objectives: Education of pediatric and adolescent patients with cancer and their families, regarding the malignancy, treatment plan, surgical plan, and risk for morbidities, is crucial. Physicians use imaging and drawings as visual aids to educate patients. However, it can be difficult for patients to understand radiological imaging. We aimed to assess the use of three‐dimensional (3D) reconstruction using virtual reality (VR) images of each patient's individual tumor to improve the quality of education during preoperative informed consent discussions. Methods: Patients with pediatric cancers and their parents from two institutions completed pre‐ and post‐test disease‐specific surveys after standard teaching and then after visualizing their tumor in VR. Survey questions included Likert scales, knowledge‐based, and open‐ended questions. The post‐test surveys also asked about their experience with VR as an educational modality. Results: Of participating families, 88.5% felt that VR should be used for all pre‐surgical consents, with the remainder of participants not answering the question. Likert‐scale ratings about VR education and free‐text comments were overall positive, and parents did not express distress when viewing the tumor in VR. Although families reported a better understanding of their child's cancer and planned surgery, answers to knowledge questions minimally increased. Conclusions: Families expressed high satisfaction with the use of VR and thought it should be used for all consent discussions. Answers to knowledge questions minimally improved, which may indicate a high level of understanding prior to VR or question and discussion content disparities. However, families reported feeling an increased understanding and felt that VR provided a positive learning environment.
- 28 September 2026
- Published by Wiley in Pediatric Blood & Cancer
Individualized Patient Education Using Virtual Reality to Prepare Families for Solid Tumor Surgery in Pediatric Oncology
Background/Objectives: Education of pediatric and adolescent patients with cancer and their families, regarding the malignancy, treatment plan, surgical plan, and risk for morbidities, is crucial. Physicians use imaging and drawings as visual aids to educate patients. However, it can be difficult for patients to understand radiological imaging. We aimed to assess the use of three‐dimensional (3D) reconstruction using virtual reality (VR) images of each patient's individual tumor to improve the quality of education during preoperative informed consent discussions. Methods: Patients with pediatric cancers and their parents from two institutions completed pre‐ and post‐test disease‐specific surveys after standard teaching and then after visualizing their tumor in VR. Survey questions included Likert scales, knowledge‐based, and open‐ended questions. The post‐test surveys also asked about their experience with VR as an educational modality. Results: Of participating families, 88.5% felt that VR should be used for all pre‐surgical consents, with the remainder of participants not answering the question. Likert‐scale ratings about VR education and free‐text comments were overall positive, and parents did not express distress when viewing the tumor in VR. Although families reported a better understanding of their child's cancer and planned surgery, answers to knowledge questions minimally increased. Conclusions: Families expressed high satisfaction with the use of VR and thought it should be used for all consent discussions. Answers to knowledge questions minimally improved, which may indicate a high level of understanding prior to VR or question and discussion content disparities. However, families reported feeling an increased understanding and felt that VR provided a positive learning environment.
- Open Access
Hu14.18K.322A Causes Direct Cell Cytotoxicity and Synergizes with Induction Chemotherapy in High-Risk Neuroblastoma
The disialoganglioside, GD2, is a promising therapeutic target due to its overexpression in certain tumors, particularly neuroblastoma (NB), with limited expression in normal tissues. Despite progress, the intricate mechanisms of action and the full spectrum of the direct cellular responses to anti-GD2 antibodies remain incompletely understood. In this study, we examined the direct cytotoxic effects of the humanized anti-GD2 antibody hu14.18K322A (hu14) on NB cell lines, by exploring the associated cell-death pathways. Additionally, we assessed the synergy between hu14 and conventional induction chemotherapy drugs. Our results revealed that hu14 treatment induced direct cytotoxic effects in CHLA15 and SK-N-BE1 cell lines, with a pronounced impact on proliferation and colony formation. Apoptosis emerged as the predominant cell-death pathway triggered by hu14. Furthermore, we saw a reduction in GD2 surface expression in response to hu14 treatment. Hu14 demonstrated synergy with induction chemotherapy drugs with alterations in GD2 expression. Our comprehensive investigation provides valuable insights into the multifaceted effects of hu14 on NB cells, shedding light on its direct cytotoxicity, cell-death pathways, and interactions with induction chemotherapy drugs. This study contributes to the evolving understanding of anti-GD2 antibody therapy and its potential synergies with conventional treatments in the context of NB.
Open AccessHu14.18K.322A Causes Direct Cell Cytotoxicity and Synergizes with Induction Chemotherapy in High-Risk Neuroblastoma
The disialoganglioside, GD2, is a promising therapeutic target due to its overexpression in certain tumors, particularly neuroblastoma (NB), with limited expression in normal tissues. Despite progress, the intricate mechanisms of action and the full spectrum of the direct cellular responses to anti-GD2 antibodies remain incompletely understood. In this study, we examined the direct cytotoxic effects of the humanized anti-GD2 antibody hu14.18K322A (hu14) on NB cell lines, by exploring the associated cell-death pathways. Additionally, we assessed the synergy between hu14 and conventional induction chemotherapy drugs. Our results revealed that hu14 treatment induced direct cytotoxic effects in CHLA15 and SK-N-BE1 cell lines, with a pronounced impact on proliferation and colony formation. Apoptosis emerged as the predominant cell-death pathway triggered by hu14. Furthermore, we saw a reduction in GD2 surface expression in response to hu14 treatment. Hu14 demonstrated synergy with induction chemotherapy drugs with alterations in GD2 expression. Our comprehensive investigation provides valuable insights into the multifaceted effects of hu14 on NB cells, shedding light on its direct cytotoxicity, cell-death pathways, and interactions with induction chemotherapy drugs. This study contributes to the evolving understanding of anti-GD2 antibody therapy and its potential synergies with conventional treatments in the context of NB.
- Open Access
- 29 November 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (2)
SARS‐CoV‐2 vaccination response in pediatric oncology patients
Background: There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients, and determine if certain clinical factors impacted response.Methods: Patients 0–25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre‐vaccination, as well as 2, 4–6, and 8–12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B‐ and T‐cell immunity, we measured neutralizing antibodies by enzyme‐linked immunoassay and interferon gamma secretion by enzyme‐linked immunospot, respectively.Results: Twenty‐six patients enrolled on study, for which 11 were evaluable oncology patients and seven were healthy controls. Adequate B‐cell response was seen in 36.4% of patients, and adequate T‐cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy.Conclusion: Pediatric oncology patients have a suboptimal immune response to SARS‐CoV‐2 vaccination. Booster doses will be imperative to provide optimal protection against COVID‐19; however, blood counts may not be a useful guide to optimize the time of administration.
- 29 November 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (2)
Open AccessSARS‐CoV‐2 vaccination response in pediatric oncology patients
Background: There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients, and determine if certain clinical factors impacted response.Methods: Patients 0–25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre‐vaccination, as well as 2, 4–6, and 8–12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B‐ and T‐cell immunity, we measured neutralizing antibodies by enzyme‐linked immunoassay and interferon gamma secretion by enzyme‐linked immunospot, respectively.Results: Twenty‐six patients enrolled on study, for which 11 were evaluable oncology patients and seven were healthy controls. Adequate B‐cell response was seen in 36.4% of patients, and adequate T‐cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy.Conclusion: Pediatric oncology patients have a suboptimal immune response to SARS‐CoV‐2 vaccination. Booster doses will be imperative to provide optimal protection against COVID‐19; however, blood counts may not be a useful guide to optimize the time of administration.
- Open Access
- 5 October 2023
- Published by Wiley
SARS-COV2 VACCINATION RESPONSE IN PEDIATRIC ONCOLOGY PATIENTS
Background: There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-COV2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients and determine if certain clinical factors impacted response. Methods: Patients 0-25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre-vaccination, as well as 2, 4-6, and 8-12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B and T cell immunity, we measured neutralizing antibodies by enzyme-linked immunoassay and interferon gamma secretion by enzyme-linked immunospot, respectively. Results: 26 patients enrolled on study, for which 11 were evaluable oncology patients and 7 were healthy controls. Adequate B cell response was seen in 36.4% of patients and adequate T cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy. Conclusion: Pediatric oncology patients have a suboptimal immune response to SARS-COV2 vaccination. Booster doses will be imperative to provide optimal protection against COVID-19, however blood counts may not be a useful guide to optimize the time of administration.
- 5 October 2023
- Published by Wiley
Open AccessSARS-COV2 VACCINATION RESPONSE IN PEDIATRIC ONCOLOGY PATIENTS
Background: There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-COV2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients and determine if certain clinical factors impacted response. Methods: Patients 0-25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre-vaccination, as well as 2, 4-6, and 8-12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B and T cell immunity, we measured neutralizing antibodies by enzyme-linked immunoassay and interferon gamma secretion by enzyme-linked immunospot, respectively. Results: 26 patients enrolled on study, for which 11 were evaluable oncology patients and 7 were healthy controls. Adequate B cell response was seen in 36.4% of patients and adequate T cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy. Conclusion: Pediatric oncology patients have a suboptimal immune response to SARS-COV2 vaccination. Booster doses will be imperative to provide optimal protection against COVID-19, however blood counts may not be a useful guide to optimize the time of administration.
- Open Access
Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer
Background: Gankyrin, a member of the 26S proteasome, is an overexpressed oncoprotein in hepatoblastoma (HBL) and hepatocellular carcinoma (HCC). Cjoc42 was the first small molecule inhibitor of Gankyrin developed; however, the IC50 values of >50 μM made them unattractive for clinical use. Second-generation inhibitors demonstrate a stronger affinity toward Gankyrin and increased cytotoxicity. The aim of this study was to characterize the in vitro effects of three cjoc42 derivatives. Methods: Experiments were performed on the HepG2 (HBL) and Hep3B (pediatric HCC) cell lines. We evaluated the expression of TSPs, cell cycle markers, and stem cell markers by Western blotting and/or real-time quantitative reverse transcription PCR. We also performed apoptotic, synergy, and methylation assays. Results: The treatment with cjoc42 derivatives led to an increase in TSPs and a dose-dependent decrease in the stem cell phenotype in both cell lines. An increase in apoptosis was only seen with AFM-1 and -2 in Hep3B cells. Drug synergy was seen with doxorubicin, and antagonism was seen with cisplatin. In the presence of cjoc42 derivatives, the 20S subunit of the 26S proteasome was more available to transport doxorubicin to the nucleus, leading to synergy. Conclusion: Small-molecule inhibitors for Gankyrin are a promising therapeutic strategy, especially in combination with doxorubicin.
Open AccessSecond Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer
Background: Gankyrin, a member of the 26S proteasome, is an overexpressed oncoprotein in hepatoblastoma (HBL) and hepatocellular carcinoma (HCC). Cjoc42 was the first small molecule inhibitor of Gankyrin developed; however, the IC50 values of >50 μM made them unattractive for clinical use. Second-generation inhibitors demonstrate a stronger affinity toward Gankyrin and increased cytotoxicity. The aim of this study was to characterize the in vitro effects of three cjoc42 derivatives. Methods: Experiments were performed on the HepG2 (HBL) and Hep3B (pediatric HCC) cell lines. We evaluated the expression of TSPs, cell cycle markers, and stem cell markers by Western blotting and/or real-time quantitative reverse transcription PCR. We also performed apoptotic, synergy, and methylation assays. Results: The treatment with cjoc42 derivatives led to an increase in TSPs and a dose-dependent decrease in the stem cell phenotype in both cell lines. An increase in apoptosis was only seen with AFM-1 and -2 in Hep3B cells. Drug synergy was seen with doxorubicin, and antagonism was seen with cisplatin. In the presence of cjoc42 derivatives, the 20S subunit of the 26S proteasome was more available to transport doxorubicin to the nucleus, leading to synergy. Conclusion: Small-molecule inhibitors for Gankyrin are a promising therapeutic strategy, especially in combination with doxorubicin.
- 15 July 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (11) , e29239
A case of progressive, metastatic adamantinoma in a pediatric patient
- 15 July 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (11) , e29239
A case of progressive, metastatic adamantinoma in a pediatric patient
- Open Access
- 19 April 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (6) , e28307
Clinical heterogeneity of pediatric hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is often a chemoresistant neoplasm with a poor prognosis. Pediatric HCC may reflect unique biological and clinical heterogeneity.Procedure: An IRB‐approved retrospective institutional review of patients with HCC treated between 2004 and 2015 was undertaken. Clinical, radiographic, and histologic data were collected from all patients.Results: Thirty‐two patients with HCC, median age 11.5 years (range 1‐20) were identified. Seventeen patients had a genetic or anatomic predisposition. Histology was conventional HCC (25) and fibrolamellar HCC (7). Evans staging was 1 (12); 2 (1); 3 (10); 4 (9). Sixteen patients underwent resection at diagnosis and five patients after neoadjuvant chemotherapy. Surgical procedures included liver transplantation (LT, 11), hemihepatectomy (9), and segmentectomy (1). Eighteen patients had medical therapy (13 neoadjuvant, 5 adjuvant). Most common initial medical therapy included sorafenib alone (7) and cisplatin/doxorubicin‐based therapy (8). Overall, 14 (43.8%) patients survived with a median follow‐up of 58.8 months (range 26.5‐157.6). Cause of death was most often linked to lack of primary tumor surgery (11). Of the survivors, Evans stage was 1 (11), 2 (1), and 3 (2, both treated with LT). Four of 18 patients (22%) who received medical therapy, 8 of 17 patients with a predisposition (47%), and 14 of 21 patients (66%) who underwent surgery remain alive.Conclusions: Genetic and anatomic predisposing conditions were seen in over half of this cohort. Evans stage 1 or 2 disease was linked to improved survival. LT trended toward improved survival. Use of known chemotherapy agents may benefit a smaller group of pediatric HCC and warrants formal prospective study through cooperative group trials.
- 19 April 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (6) , e28307
Open AccessClinical heterogeneity of pediatric hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is often a chemoresistant neoplasm with a poor prognosis. Pediatric HCC may reflect unique biological and clinical heterogeneity.Procedure: An IRB‐approved retrospective institutional review of patients with HCC treated between 2004 and 2015 was undertaken. Clinical, radiographic, and histologic data were collected from all patients.Results: Thirty‐two patients with HCC, median age 11.5 years (range 1‐20) were identified. Seventeen patients had a genetic or anatomic predisposition. Histology was conventional HCC (25) and fibrolamellar HCC (7). Evans staging was 1 (12); 2 (1); 3 (10); 4 (9). Sixteen patients underwent resection at diagnosis and five patients after neoadjuvant chemotherapy. Surgical procedures included liver transplantation (LT, 11), hemihepatectomy (9), and segmentectomy (1). Eighteen patients had medical therapy (13 neoadjuvant, 5 adjuvant). Most common initial medical therapy included sorafenib alone (7) and cisplatin/doxorubicin‐based therapy (8). Overall, 14 (43.8%) patients survived with a median follow‐up of 58.8 months (range 26.5‐157.6). Cause of death was most often linked to lack of primary tumor surgery (11). Of the survivors, Evans stage was 1 (11), 2 (1), and 3 (2, both treated with LT). Four of 18 patients (22%) who received medical therapy, 8 of 17 patients with a predisposition (47%), and 14 of 21 patients (66%) who underwent surgery remain alive.Conclusions: Genetic and anatomic predisposing conditions were seen in over half of this cohort. Evans stage 1 or 2 disease was linked to improved survival. LT trended toward improved survival. Use of known chemotherapy agents may benefit a smaller group of pediatric HCC and warrants formal prospective study through cooperative group trials.
- 5 August 2019
- Published by Wiley in Psycho-Oncology
- Vol. 28 (10) , 2009-2016
Internalizing symptoms in AYA survivors of childhood cancer and matched comparisons
Objective: As the number of pediatric cancer survivors increases, so does our need to understand behavioral late effects. Prior studies show mixed results, with some noting increased emotional distress and psychiatric diagnoses in cancer survivors and others suggesting resilience. The purpose of our study was to evaluate internalizing symptoms such as anxiety and depression in young adult survivors of childhood cancer compared with matched classroom matched peers.Method: We completed a multisource, cross‐sectional examination of internalizing symptoms using a semistructured psychiatric interview with 18‐year‐olds with a history of pediatric cancer compared with age, race, and gender matched classroom peers who had been identified during the survivor's first year of treatment and their primary caregivers.Results: Fifty‐seven young adult survivors of childhood cancer and 60 comparison peers participated. There were no significant differences between survivors and their peers on the basis of self‐ or parent‐reported depressive or anxiety symptoms or number of psychiatric diagnoses.Conclusions: Young adult survivors of childhood cancer and their parents did not report increased rates of anxiety or depression compared with their former classroom peers. Despite experiencing a major life challenge, this group of young adults with cancer did not report more current or past symptoms of internalizing psychopathology.
- 5 August 2019
- Published by Wiley in Psycho-Oncology
- Vol. 28 (10) , 2009-2016
Internalizing symptoms in AYA survivors of childhood cancer and matched comparisons
Objective: As the number of pediatric cancer survivors increases, so does our need to understand behavioral late effects. Prior studies show mixed results, with some noting increased emotional distress and psychiatric diagnoses in cancer survivors and others suggesting resilience. The purpose of our study was to evaluate internalizing symptoms such as anxiety and depression in young adult survivors of childhood cancer compared with matched classroom matched peers.Method: We completed a multisource, cross‐sectional examination of internalizing symptoms using a semistructured psychiatric interview with 18‐year‐olds with a history of pediatric cancer compared with age, race, and gender matched classroom peers who had been identified during the survivor's first year of treatment and their primary caregivers.Results: Fifty‐seven young adult survivors of childhood cancer and 60 comparison peers participated. There were no significant differences between survivors and their peers on the basis of self‐ or parent‐reported depressive or anxiety symptoms or number of psychiatric diagnoses.Conclusions: Young adult survivors of childhood cancer and their parents did not report increased rates of anxiety or depression compared with their former classroom peers. Despite experiencing a major life challenge, this group of young adults with cancer did not report more current or past symptoms of internalizing psychopathology.
- 3 July 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (11) , e27293
Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is an aggressive malignant neoplasm that is often chemoresistant. Complete surgical resection remains the mainstay of therapy. The role of liver transplantation (LT) in pediatric HCC is in evolution, as is the role of adjuvant chemotherapy for stage I disease.Methods: A retrospective review of patients < 18 years of age with completely resected HCC treated with surgical intervention alone at our institution from 2004 to 2015 was conducted.Results: Twelve patients with a median age of 12 years (range = 1–17; number of females = 7) with upfront resected HCC (Evans stage I) were identified. Four patients had HCC without identifiable risk factors (fibrolamellar‐HCC = 2; early HCC arising in focal nodular hyperplasia = 1, well‐differentiated [wd] HCC = 1). Four patients had early or wd‐HCC in the context of portosystemic shunts (Abernethy = 2; mesocaval shunt and portal vein thrombosis = 2). Four patients had moderate to wd‐HCC in the context of pre‐existing liver disease with cirrhosis (progressive familial intrahepatic cholestasis type‐2 = 2, alpha‐1 antitrypsin deficiency = 1, Alagille syndrome = 1). Seven patients underwent LT (multifocal = 5; solitary = 2); five exceeded Milan criteria (MC) by imaging. Five patients underwent complete resection (segmentectomy = 2; hemihepatectomy = 3). Ten patients received no adjuvant chemotherapy. All patients are alive without evidence of disease with a median follow‐up of 54.1 months (range = 28.1–157.7 months).Conclusions: Pediatric and adolescent patients with upfront, completely resected HCC can be effectively treated without chemotherapy. LT should be considered for nonmetastatic HCC, especially in the context of pre‐existing chronic liver disease, even when the tumor exceeds MC. Distinct pediatric selection criteria are needed to identify patients most suitable for LT.
- 3 July 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (11) , e27293
Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is an aggressive malignant neoplasm that is often chemoresistant. Complete surgical resection remains the mainstay of therapy. The role of liver transplantation (LT) in pediatric HCC is in evolution, as is the role of adjuvant chemotherapy for stage I disease.Methods: A retrospective review of patients < 18 years of age with completely resected HCC treated with surgical intervention alone at our institution from 2004 to 2015 was conducted.Results: Twelve patients with a median age of 12 years (range = 1–17; number of females = 7) with upfront resected HCC (Evans stage I) were identified. Four patients had HCC without identifiable risk factors (fibrolamellar‐HCC = 2; early HCC arising in focal nodular hyperplasia = 1, well‐differentiated [wd] HCC = 1). Four patients had early or wd‐HCC in the context of portosystemic shunts (Abernethy = 2; mesocaval shunt and portal vein thrombosis = 2). Four patients had moderate to wd‐HCC in the context of pre‐existing liver disease with cirrhosis (progressive familial intrahepatic cholestasis type‐2 = 2, alpha‐1 antitrypsin deficiency = 1, Alagille syndrome = 1). Seven patients underwent LT (multifocal = 5; solitary = 2); five exceeded Milan criteria (MC) by imaging. Five patients underwent complete resection (segmentectomy = 2; hemihepatectomy = 3). Ten patients received no adjuvant chemotherapy. All patients are alive without evidence of disease with a median follow‐up of 54.1 months (range = 28.1–157.7 months).Conclusions: Pediatric and adolescent patients with upfront, completely resected HCC can be effectively treated without chemotherapy. LT should be considered for nonmetastatic HCC, especially in the context of pre‐existing chronic liver disease, even when the tumor exceeds MC. Distinct pediatric selection criteria are needed to identify patients most suitable for LT.